Endometriosis and ovarian cancer: Thoughts on shared pathophysiology

被引:181
作者
Ness, RB
机构
[1] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Inst Canc, Pittsburgh, PA 15261 USA
[2] Magee Womens Res Inst, Pittsburgh, PA USA
关键词
endometriosis; estrogen; inflammation; ovarian cancer; progesterone;
D O I
10.1067/mob.2003.408
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Endometriosis appears to predispose to ovarian cancer. How this may occur has been little discussed. STUDY DESIGN: This article reviews the English language literature for in vitro, animal, clinical, and epidemiologic studies linking the two conditions. RESULTS: Pathology case series consistently report endometrioid and clear cell types of ovarian cancer arising from endometriotic foci. Epidemiologic studies have been consistent with this association. There are also marked similarities between the proposed etiology of ovarian cancer and the observed pathophysiology of endometriosis. Specifically, both are characterized by immune alterations. Both conditions are promoted by estrogen excess and by progesterone deficit. Finally, steroid hormones interacting with the immune system may stimulate both endometriosis and ovarian cancer. I propose that the biology common to endometriosis and ovarian cancer represents not just a parallelism, but instead a causal pathway: aberrant immune function, fed by and feeding on estrogens, unbalanced by progesterone, may create a positive feed-forward loop that enhances the growth and invasiveness of endometriosis and promotes its malignant transformation. CONCLUSIONS: The same pathophysiology may orchestrate the progression of endometriosis and its transformation to endometroid and clear cell ovarian neoplasias. This notion of a unifying biology suggests a directed approach to future research and identifies possible chemoprevention strategies for women with endometriosis.
引用
收藏
页码:280 / 294
页数:15
相关论文
共 273 条
[1]  
ACHESON ED, 1982, BRIT J IND MED, V39, P344
[2]   PARITY, AGE AT FIRST CHILDBIRTH, AND RISK OF OVARIAN-CANCER [J].
ADAMI, HO ;
HSIEH, CC ;
LAMBE, M ;
TRICHOPOULOS, D ;
LEON, D ;
PERSSON, I ;
EKBOM, A ;
JANSON, PO .
LANCET, 1994, 344 (8932) :1250-1254
[3]  
Adashi EY, 1998, MOL CELL ENDOCRINOL, V140, P77, DOI 10.1016/S0303-7207(98)00038-0
[4]   Aspirin and epithelial ovarian cancer [J].
Akhmedkhanov, A ;
Toniolo, P ;
Zeleniuch-Jacquotte, A ;
Kato, I ;
Koenig, KL ;
Shore, RE .
PREVENTIVE MEDICINE, 2001, 33 (06) :682-687
[5]   Luteinizing hormone, its β-subunit variant, and epithelial ovarian cancer:: The gonadotropin hypothesis revisited [J].
Akhmedkhanov, A ;
Toniolo, P ;
Zeleniuch-Jacquotte, A ;
Pettersson, KS ;
Huhtaniemi, IT .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 154 (01) :43-49
[6]  
Akoum A, 1996, HUM REPROD, V11, P2269
[7]   THE CAUSES AND PREVENTION OF CANCER [J].
AMES, BN ;
GOLD, LS ;
WILLETT, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5258-5265
[8]   Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases [J].
Andersson, S ;
Moghrabi, N .
STEROIDS, 1997, 62 (01) :143-147
[9]  
Asschert JGW, 1999, INT J CANCER, V82, P244, DOI 10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO
[10]  
2-N